Table 1.

Clinical trials on stimulant medication in adults with ADHD

Simulants’ study	N	Method	Outcome	Conclusion
Short-acting stimulants
MPH* (Spencer et al 1995)	23	Duble-blind crossover study	ADHD symptoms ↓ (78%)	MPH is significantly more effective than placebo
MPH (Spencer et al 2005)	146	Duble-blind randomized study	ADHD symptoms ↓ (76%) No serious CV adverse events	MPH is significantly more effective than placebo Good tolerability
Long-acting stimulants
Controlled release MPH/Biphentin/ (Jain et al 2007)	39	Double-blind placebo-controlled crossover study	ADHD symptoms ↓ Weight loss	Successful in symptoms control Well tolerated
OROS-MPH/Concerta/(Fallu et al 2006)	32	Uncontrolled, open label study	ADHD symptoms ↓ Functional improvements (Sheehan scale)	Successful control of symptoms Less functional disability
OROS-MPH/Concerta/ (Biederman et al 2006)	141	Double-blind, randomized, placebo controlled study	ADHD symptoms ↓ ↑Systolic and diastolic blood pressure and heart rate	Successful control of symptoms Concerns about CV tolerability
OROS-MPH/Concerta/ (Reimherr et al 2007)	47	Double-blind, placebo-controlled, crossover study	ADHD symptoms ↓ (41%–42% symptoms reduction)	Less remarkable improvement than in other comparable studies
Mixed amphetamine salts XR/Adderall XR/(Biederman et al 2005)	223	Double-blind, placebo-controlled study	ADHD symptoms ↓ (sustained improvement up to 24 months) Good tolerance	Sustained symptomatic impovement Well tolerated

^*MPH – methylphenidate